Skip to content
10-Q

Quarterly Report

Mineralys Therapeutics, Inc. MLYS

0001933414-25-000058

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 8, 2025 65.18M sh
Capex Q1 2025 · Mar 31, 2025 $0
Capex Q1 2025 · Mar 31, 2024 $59K
Cash And Equivalents Q1 2025 · Mar 31, 2025 $165.01M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $114.09M
Current Liabilities Q1 2025 · Mar 31, 2025 $13.39M
Current Liabilities Q1 2025 · Dec 31, 2024 $14.65M
Current Assets Q1 2025 · Mar 31, 2025 $354.51M
Current Assets Q1 2025 · Dec 31, 2024 $205.35M
Total Assets Q1 2025 · Mar 31, 2025 $354.94M
Total Assets Q1 2025 · Dec 31, 2024 $205.9M
Shares Diluted Q1 2025 · Mar 31, 2024 44.9M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$19.14M
Stockholders Equity Q1 2025 · Mar 31, 2024 $328.05M
Stockholders Equity Q1 2025 · Dec 31, 2023 $241.15M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.70
Eps Basic Q1 2025 · Mar 31, 2024 −$0.70
Sga Expense Q1 2025 · Mar 31, 2024 $4.61M
Rd Expense Q1 2025 · Mar 31, 2024 $30.75M
Net Income Q1 2025 · Mar 31, 2024 −$31.51M
Operating Income Q1 2025 · Mar 31, 2024 −$35.36M